These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 17102124)

  • 1. Pathology of pheochromocytoma and extra-adrenal paraganglioma.
    Tischler AS; Kimura N; Mcnicol AM
    Ann N Y Acad Sci; 2006 Aug; 1073():557-70. PubMed ID: 17102124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pheochromocytoma and extra-adrenal paraganglioma: updates.
    Tischler AS
    Arch Pathol Lab Med; 2008 Aug; 132(8):1272-84. PubMed ID: 18684026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
    Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
    Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pheochromocytoma and sympathetic paragangliomas].
    Zollinger R; Hedinger C
    Schweiz Med Wochenschr; 1983 Jul; 113(30):1057-65. PubMed ID: 6623024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonsporadic cases and unusual morphological features in pheochromocytoma and paraganglioma.
    Lamovec J; Frković-Grazio S; Bracko M
    Arch Pathol Lab Med; 1998 Jan; 122(1):63-8. PubMed ID: 9448019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Malignant pheochromocytoma. A case report and comments on a rare pathology].
    Boneschi M; Erba M; Rinaldi P; Cusmai F; Miani S
    Minerva Chir; 1999; 54(1-2):73-8. PubMed ID: 10230231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
    Guo Z; Lloyd RV
    Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-tumoral molecular heterogeneity in benign and malignant pheochromocytomas and extra-adrenal sympathetic paragangliomas.
    Korpershoek E; Stobbe CK; van Nederveen FH; de Krijger RR; Dinjens WN
    Endocr Relat Cancer; 2010 Sep; 17(3):653-62. PubMed ID: 20488782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometric DNA analysis for the determination of malignant potential in adrenal and extra-adrenal pheochromocytomas or paragangliomas.
    Pang LC; Tsao KC
    Arch Pathol Lab Med; 1993 Nov; 117(11):1142-7. PubMed ID: 8239937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental gene expression of sympathetic nervous system tumors reflects their histogenesis.
    Hoehner JC; Hedborg F; Eriksson L; Sandstedt B; Grimelius L; Olsen L; Påhlman S
    Lab Invest; 1998 Jan; 78(1):29-45. PubMed ID: 9461120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenal and extra-adrenal nonfunctioning composite pheochromocytoma/paraganglioma with immunohistochemical ectopic hormone expression: comparison of two cases.
    Gong J; Wang X; Chen X; Chen N; Huang R; Lu C; Chen D; Zeng H; Zhou Q
    Urol Int; 2010; 85(3):368-72. PubMed ID: 20829582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics of adrenal tumors.
    Opocher G; Schiavi F; Cicala MV; Patalano A; Mariniello B; Boaretto F; Zovato S; Pignataro V; Macino B; Negro I; Mantero F
    Minerva Endocrinol; 2009 Jun; 34(2):107-21. PubMed ID: 19471236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tumors of the adrenal medulla and the paraganglia].
    Klöppel G
    Pathologe; 2003 Jul; 24(4):280-6. PubMed ID: 14513275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paragangliomas: etiology, presentation, and management.
    Joynt KE; Moslehi JJ; Baughman KL
    Cardiol Rev; 2009; 17(4):159-64. PubMed ID: 19525677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
    Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
    J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignancy in pheochromocytomas.
    Salmenkivi K; Heikkilä P; Haglund C; Arola J
    APMIS; 2004 Sep; 112(9):551-9. PubMed ID: 15601303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 15 YEARS OF PARAGANGLIOMA: Pathology of pheochromocytoma and paraganglioma.
    Tischler AS; deKrijger RR
    Endocr Relat Cancer; 2015 Aug; 22(4):T123-33. PubMed ID: 26136457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
    Chrisoulidou A; Kaltsas G; Ilias I; Grossman AB
    Endocr Relat Cancer; 2007 Sep; 14(3):569-85. PubMed ID: 17914089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phaeochromocytoma: a catecholamine and oxidative stress disorder.
    Pacak K
    Endocr Regul; 2011 Apr; 45(2):65-90. PubMed ID: 21615192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathology and immunohistochemistry of adrenal medullary tumors and paragangliomas.
    McNicol AM
    Endocr Pathol; 2006; 17(4):329-36. PubMed ID: 17525481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.